Clinical Trials Browser

NCT05947838 2026-05-18

A Prospective Feasibility Study Using ctDNA to Tailor Neoadjuvant Chemotherapy for Patients With Colorectal or Appendiceal Adenocarcinoma

Phase NA Recruiting

48 enrolled

Adenocarcinoma, Mucinous

NCT07587268 2026-05-14

Molecular Profiling for Risk Stratification in Appendiceal Cancer

Recruiting

400 enrolled

Gastrointestinal

Appendiceal Neoplasms, Adenocarcinoma, Mucinous

NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Phase 2 Active not recruiting

133 enrolled

DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

NCT06207305 2026-01-13

A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma

Phase 1/2 Recruiting

39 enrolled

Adenocarcinoma, Mucinous

NCT05504252 2026-01-07

METIMMOX-2

Phase 2 Active not recruiting

80 enrolled

Adenocarcinoma, Mucinous, Carcinoma, Signet Ring Cell

NCT03108131 2025-05-28

Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

Phase 2 Completed

49 enrolled 10 charts

Adenocarcinoma, Mucinous, Neoplasm Metastasis, Neoplasms

NCT05734430 2025-04-18

GAP

Recruiting

700 enrolled

Gastrointestinal

Appendiceal Neoplasms, Adenocarcinoma, Mucinous

NCT06182644 2024-01-22

FAPI

Phase NA Unknown

30 enrolled

GastrointestinalGenitourinary

Adenocarcinoma, Mucinous, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Signet Ring Cell

NCT04088786 2022-05-06

Phase I Trial HIPEC With Nal-irinotecan

Phase 1 Completed

18 enrolled

GastrointestinalOther solid neoplasmThoracic

Adenocarcinoma, Mucinous, Mesothelioma, Pseudomyxoma Peritonei, Stomach Neoplasms, Colorectal Neoplasms, Neoplasms, Cystic, Mucinous, and Serous

NCT03466034 2020-01-29

The Role of Hypoxia as a Selective Pressure for TP53 Mutations

Terminated

5 enrolled

Gynecologic

Hypoxia, Adenocarcinoma, Mucinous, Endometrial Neoplasms

NCT02005965 2018-09-18

Adenocarcinoma, Carcinoma, Adenocarcinoma, Mucinous, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Rectal Diseases, Rectal Neoplasms, Colorectal Neoplasms, Neoplasms, Cystic, Mucinous, and Serous

NCT01037049 2018-09-17

Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks

Phase 2 Unknown

237 enrolled

Gastrointestinal

Adenocarcinoma, Carcinoma, Adenocarcinoma, Mucinous, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Rectal Diseases, Rectal Neoplasms, Colorectal Neoplasms, Neoplasms, Cystic, Mucinous, and Serous

NCT01995942 2018-09-14

MARVEL

Unknown

246 enrolled

Gastrointestinal

Adenocarcinoma, Carcinoma, Adenocarcinoma, Mucinous, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Rectal Diseases, Rectal Neoplasms, Colorectal Neoplasms, Neoplasms, Cystic, Mucinous, and Serous

Clinical Trials

A Prospective Feasibility Study Using ctDNA to Tailor Neoadjuvant Chemotherapy for Patients With Colorectal or Appendiceal Adenocarcinoma

Molecular Profiling for Risk Stratification in Appendiceal Cancer

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma

METIMMOX-2

Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

GAP

FAPI

Phase I Trial HIPEC With Nal-irinotecan

The Role of Hypoxia as a Selective Pressure for TP53 Mutations

MERCURY II

Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks

MARVEL